Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GLS | O94925 | 3/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23485806 | 0.87 | CYP2C19 (0.41) | GLSATML3MBTL1LMNACHRM1 | |
| SCHEMBL28782325 | 0.83 | ADRB2 (0.41) | KMT2AL3MBTL1LMNA | |
| SCHEMBL28594279 | 0.82 | CYP2C19 (0.45) | KMT2ABTN3A1MEN1LMNAESR1 | |
| SCHEMBL24810045 | 0.81 | SMN1; SMN2 (0.37) | KMT2ABTN3A1MEN1LMNA | |
| SCHEMBL7974655 | 0.79 | AMPD2 (0.41) | KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL28782293 | 0.78 | ALDH1A1 (0.56) | KMT2ABTN3A1L3MBTL1MEN1LMNA | |
| SCHEMBL27094502 | 0.77 | RIPK1 (0.53) | L3MBTL1LMNA | |
| SCHEMBL1520904 | 0.77 | RIPK1 (0.53) | L3MBTL1LMNA | |
| SCHEMBL16798382 | 0.76 | CYP2C19 (0.42) | KMT2AGLSATML3MBTL1MEN1 | |
| SCHEMBL1969671 | 0.75 | TARBP2 (0.36) | KMT2AATMMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | BTK, SYK, LYN | KMT2A 732/4885GLS 3841/4885BTN3A1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.